News in Numbers


The French drug manufacturer Laboratoires Servier has been fined €2.7m (£2.3m) for concealing potentially fatal side effects of the widely prescribed drug Mediator.


GlobaldData forecasts that Pfizer/BioNTech’s vaccine will achieve record-breaking sales of $24.8bn by 2021.

2.4 million 

The Czech Republic wants to buy around 2.4 million doses of the AstraZeneca/Oxford University vaccine ditched by Denmark, which has said it will stop using it because of concerns about rare blood clotting side effects.


An injection, known as PHESGO, which cuts the amount of time breast cancer patients spend in hospital from two and a half hours to as little as five minutes is being rolled out across the country by NHS England.

3 million

The number of diagnosed prevalent cases of Parkinson’s disease is on track to reach 3 million by 2029 in the 7MM, according to GlobalData research. 



The US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for the novel combined oral contraceptive NEXTSTELLIS (3 mg drospirenone and 14.2 mg of estetrol tablets). 

Source: Pharmaceutical Technology 


The UK Medicines and Healthcare products Regulatory Agency has approved a new subcutaneous formulation for Biogen’s multiple sclerosis treatment Tysabri.

Source: MS Trust


China’s National Medical Products Administration has approved Biogen’s TECFIDERA (dimethyl fumarate) for the treatment of relapsing multiple sclerosis. 

Source: Yahoo finance


The European Commission has approved Bristol Myers Squibb’s drug nivolumab in combination with cabozantinib as a treatment for patients with advanced renal cell carcinoma.

Source: Market Watch

Sputnik V

India has granted emergency use authorisation for Russia’s Sputnik V vaccine, becoming the 60th country to approve the vaccine. 

Source: CNBC

Clinical Trials

PTC’s Evrysdi improves motor function and survival in infants with SMA 

Results from Part 2 of the PTC Therapeutics’ FIREFISH trial of Evrysdi reportedly demonstrated that infants with type 1 spinal muscular atrophy continued to show improvements in survival and key motor milestones after two years of treatment.

Source: PTC Therapeutics

Ideaya doses first patient in solid tumour treatment trial

Ideaya Biosciences has announced first-patient-in (FPI) in Phase I clinical trial of methionine adenosyltransferase 2a inhibitor IDE397 for treating methylthioadenosine phosphorylase deletion solid tumours.

Source: Clinical Trials Arena

Romark’s investigational Covid-19 drug lowers disease progression in trial

Romark has reported that initial results from a Phase III clinical trial of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets, 300mg) showed reduced disease progression in mild or moderate Covid-19 patients.

Source: Romark

GSK to halt two cancer trials of investigational ICOS agonist

GlaxoSmithKline (GSK) has decided to stop the enrolment of patients in Phase II INDUCE-3 trial of feladilimab for PD-L1 positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma treatment.

Source: Clinical Trials Arena

Oxford University expands Com-COV2 dose-mixing study with Novavax’s Covid-19 vaccine

The University of Oxford has expanded the Comparing Covid-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2) study to include the Novavax and Moderna vaccines for the disease treatment.

Source: Pharmaceutical Technology

Rigel’s fostamatinib meets primary endpoint in Covid-19 clinical trial

Rigel Pharmaceuticals has reported that the Phase II clinical trial of its oral spleen tyrosine kinase inhibitor fostamatinib in treating hospitalised Covid-19 patients met the primary endpoint of safety.

Source: Rigel